Definium Therapeutics/$DFTX
1D1W1MYTD1Y5YMAX
Capital at risk
About Definium Therapeutics
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
- Ticker
- $DFTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- New York, United States
- Website
- definiumtx.com
DFTX Metrics
BasicAdvanced
$5.1B
-
-$3.48
2.26
-
Price and volume
Market cap
$5.1B
Beta
2.26
52-week high
$49.70
52-week low
$8.77
Average daily volume
2.3M
Financial strength
Current ratio
6.947
Quick ratio
6.895
Long term debt to equity
0.04
Total debt to equity
0.04
Interest coverage (TTM)
-45.33%
Profitability
Management effectiveness
Return on assets (TTM)
-20.64%
Return on equity (TTM)
-64.09%
Valuation
Price to book
5.54
Price to tangible book (TTM)
5.66
Price to free cash flow (TTM)
-22.896
Free cash flow yield (TTM)
-4.37%
Free cash flow per share (TTM)
-1.653
Growth
Earnings per share change (TTM)
143.13%
3-year earnings per share growth (CAGR)
18.37%
What the Analysts think about DFTX
Analyst ratings (Buy, Hold, Sell) for Definium Therapeutics stock.
Analyst projections of the future price of Definium Therapeutics stock.
Bulls say / Bears say
DT120 has now produced three positive Phase 3 readouts: two in GAD and one in MDD. The placebo-adjusted improvements were 5.4 points on HAM-A in Voyage, 5.1 points in Panorama and 8.1 points on MADRS in Emerge, giving the programme unusually consistent late-stage evidence. (Definium Therapeutics, Clinical Trials Arena)
The FDA has granted DT120 Breakthrough Therapy designation for both GAD and MDD. That status can speed development and review, while the MDD designation was supported by a statistically significant and durable Phase 3 result. (Definium Therapeutics)
Definium ended June with about $1.1 billion in cash, cash equivalents and investments after raising roughly $758 million net from a share offering. Management says this should fund operations into 2030, giving it time to complete trials, file an NDA and prepare for a potential launch without near-term financing pressure. (Definium Therapeutics)
DT120 is not yet approved or even at the filing stage. Definium only expects a pre-NDA meeting in the fourth quarter of 2026 and an NDA filing in the first half of 2027, leaving material FDA, scheduling and review risk before any commercial revenue. (PharmaDeviceNews, Definium Therapeutics)
The treatment still causes frequent acute psychedelic effects, including illusions and nausea. Even without drug-related serious adverse events in Panorama, these effects could make supervised delivery, patient acceptance and broad commercial adoption harder than for conventional tablets. (StockTitan, PharmaDeviceNews)
The company remains loss-making and is relying on shareholders to fund its expansion: its second-quarter net loss was $159 million and it raised about $758 million net through a large share offering. Further development and commercial-readiness spending could therefore bring more dilution before DT120 generates revenue. (Definium Therapeutics, StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.
DFTX Financial Performance
Revenues and expenses
DFTX Earnings Performance
Company profitability
Upcoming events
No upcoming events
DFTX News
AllArticlesVideos
Definium Says Its Anxiety Drug Showed 'Unprecedented Efficacy'
Benzinga3 days ago
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026
Business Wire1 week ago
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
Business Wire3 weeks ago
Funds containing DFTX
AllUSDGBPEUR
Fund name | Fund size | $DFTX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.27% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.27% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.16% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.11% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.11% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.